UK markets closed

PURE Bioscience, Inc. (PURE)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.0700-0.0090 (-11.39%)
At close: 03:07PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 7.83M
Enterprise value 9.13M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.80
Price/book (mrq)5.57
Enterprise value/revenue 4.44
Enterprise value/EBITDA -2.65

Trading information

Stock price history

Beta (5Y monthly) 0.06
52-week change 3-42.86%
S&P500 52-week change 322.38%
52-week high 30.1700
52-week low 30.0600
50-day moving average 30.0866
200-day moving average 30.1062

Share statistics

Avg vol (3-month) 322.93k
Avg vol (10-day) 310.89k
Shares outstanding 5111.86M
Implied shares outstanding 6126.24M
Float 866.61M
% held by insiders 140.45%
% held by institutions 10.00%
Shares short (30 Apr 2013) 4222.97k
Short ratio (30 Apr 2013) 42.56
Short % of float (30 Apr 2013) 41.86%
Short % of shares outstanding (30 Apr 2013) 41.82%
Shares short (prior month 28 Mar 2013) 4254.8k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:8
Last split date 315 Aug 2012

Financial highlights

Fiscal year

Fiscal year ends 31 Jul 2023
Most-recent quarter (mrq)31 Jan 2024

Profitability

Profit margin -177.20%
Operating margin (ttm)-295.71%

Management effectiveness

Return on assets (ttm)-112.66%
Return on equity (ttm)-977.21%

Income statement

Revenue (ttm)2.06M
Revenue per share (ttm)0.02
Quarterly revenue growth (yoy)-17.90%
Gross profit (ttm)N/A
EBITDA -3.13M
Net income avi to common (ttm)-3.65M
Diluted EPS (ttm)-0.0400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)557k
Total cash per share (mrq)0
Total debt (mrq)1.86M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.72
Book value per share (mrq)-0.01

Cash flow statement

Operating cash flow (ttm)-2.73M
Levered free cash flow (ttm)-1.54M